Scholarlink

<p>Retinal detachment (RD) triggers a neuroinflammatory response aimed at clearing damaged photoreceptors (PR) and limiting injury. However, this response can unintentionally worsen retinal neurodegeneration. Retinal microglia (MG) and infiltrating monocytes (Mø) play key roles in this process and are regulated by the colony-stimulating factor 1 receptor (CSF1R). Targeting the CSF1R has been proposed as a potential strategy to modulate neuroinflammation. Using PLX5622, a selective CSF1R inhibitor, we examined the local and systemic immune effects in RD in a novel experimental model with specific MG and Mø labeling. We found that PLX5622 depletes and alters the function of MG and Mø subtypes, modulates myeloid cell infiltration into the retina, and confers neuroprotection to PRs in both acute and chronic phases of RD. These findings highlight that CSF1R inhibition could create a therapeutic window to mitigate early inflammatory damage. Targeting CSF1R may represent a promising therapeutic strategy for neuroprotection in RD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Colony-stimulating factor 1 receptor inhibition is neuroprotective to photoreceptors in retinal detachment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Sara Pastor-Puente,
  • Rebecca Jung,
  • Lucia Gonzalez-Buendia,
  • Eleftherios I. Paschalis,
  • Demetrios G. Vavvas,
  • Andrius Kazlauskas,
  • Daniel E. Maidana

摘要

Retinal detachment (RD) triggers a neuroinflammatory response aimed at clearing damaged photoreceptors (PR) and limiting injury. However, this response can unintentionally worsen retinal neurodegeneration. Retinal microglia (MG) and infiltrating monocytes (Mø) play key roles in this process and are regulated by the colony-stimulating factor 1 receptor (CSF1R). Targeting the CSF1R has been proposed as a potential strategy to modulate neuroinflammation. Using PLX5622, a selective CSF1R inhibitor, we examined the local and systemic immune effects in RD in a novel experimental model with specific MG and Mø labeling. We found that PLX5622 depletes and alters the function of MG and Mø subtypes, modulates myeloid cell infiltration into the retina, and confers neuroprotection to PRs in both acute and chronic phases of RD. These findings highlight that CSF1R inhibition could create a therapeutic window to mitigate early inflammatory damage. Targeting CSF1R may represent a promising therapeutic strategy for neuroprotection in RD.